Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

International Organization for the Study of Inflammatory Bowel Disease

doi:10.1053/j.gastro.2020.04.002

Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

International Organization for the Study of Inflammatory Bowel Disease

Faculty of Medicine

Research output: Contribution to journal › Editorial

164 Scopus citations

Original language	American English
Pages (from-to)	6-13.e6
Journal	Gastroenterology
Volume	159
Issue number	1
DOIs	https://doi.org/10.1053/j.gastro.2020.04.002
State	Published - Jul 2020

Bibliographical note

Funding Information:
Conflicts of interest The authors have made the following disclosures: David Rubin, Maria Abreu, and Corey Siegel are members of IOIBD. In addition, they have the following disclosures. David T. Rubin has received grant support from Takeda ; has served as a consultant for Abbvie, Abgenomics, Allergan Inc., Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., GlaxoSmithKline Services, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc. Maria T. Abreu has received grant support from Prometheus Laboratories , Pfizer , and Takeda; and has served as a consultant for Abbvie, Eli Lilly, Janssen, Takeda, Focus Medical Communications, Boehringer Ingelheim, Gilead, Imedex, Cornerstones Health, Landos Biopharma, and UCB Biopharma SRL. Victoria Rai has nothing to disclose. Corey A. Siegel has received grant support from the Crohn’s and Colitis Foundation , Broad Medical Research Program , Abbvie , Janssen , Pfizer, and Takeda; and has served as consultant for Abbvie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Pfizer, Prometheus, Sebela, and Takeda.

Funding Information:
Conflicts of interest The authors have made the following disclosures: David Rubin, Maria Abreu, and Corey Siegel are members of IOIBD. In addition, they have the following disclosures. David T. Rubin has received grant support from Takeda; has served as a consultant for Abbvie, Abgenomics, Allergan Inc., Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., GlaxoSmithKline Services, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc. Maria T. Abreu has received grant support from Prometheus Laboratories, Pfizer, and Takeda; and has served as a consultant for Abbvie, Eli Lilly, Janssen, Takeda, Focus Medical Communications, Boehringer Ingelheim, Gilead, Imedex, Cornerstones Health, Landos Biopharma, and UCB Biopharma SRL. Victoria Rai has nothing to disclose. Corey A. Siegel has received grant support from the Crohn's and Colitis Foundation, Broad Medical Research Program, Abbvie, Janssen, Pfizer, and Takeda; and has served as consultant for Abbvie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Pfizer, Prometheus, Sebela, and Takeda.

Access to Document

10.1053/j.gastro.2020.04.002

Cite this

@article{16aeb9142ee543749516c418480068fa,

title = "Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting",

author = "{International Organization for the Study of Inflammatory Bowel Disease} and Rubin, {David T.} and Abreu, {Maria T.} and Victoria Rai and Siegel, {Corey A.} and Vineet Ahuja and Matthieu Allez and Ananthakrishnan, {Ashwin N.} and Bernstein, {Charles N.} and Braun, {Jonathan G.} and Yehuda Chowers and Colombel, {Jean Frederic} and Silvio Danese and Geert D'Haens and Andre D'Hoore and Axel Dignass and Iris Dotan and Dubinsky, {Marla C.} and Anders Ekbom and Fleshner, {Phillip R.} and Gassull, {Miquel A.} and Gearry, {Richard B.} and Subrata Ghosh and Griffiths, {Anne M.} and Jonas Halfvarson and Hanauer, {Stephen B.} and Noam Harpaz and Ailsa Hart and Kamm, {Michael A.} and Kaplan, {Gil G.} and Ioannis Koutroubakis and Lakatos, {Peter L.} and Arie Levine and Lewis, {James D.} and Lindsay, {James O.} and Loftus, {Edward V.} and Edouard Louis and Milan Lukas and Fernando Magro and Uma Mahadevan and Mantzaris, {Gerasimos J.} and McGovern, {Dermot P.} and Moum, {Bj{\o}rn A.} and Pia Munkholm and Neurath, {Markus F.} and Ng, {Siew C.} and Colm O'Morain and Remo Panaccione and Julian Panes and Laurent Peyrin-Biroulet and Dan Turner",

note = "Funding Information: Conflicts of interest The authors have made the following disclosures: David Rubin, Maria Abreu, and Corey Siegel are members of IOIBD. In addition, they have the following disclosures. David T. Rubin has received grant support from Takeda ; has served as a consultant for Abbvie, Abgenomics, Allergan Inc., Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., GlaxoSmithKline Services, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc. Maria T. Abreu has received grant support from Prometheus Laboratories , Pfizer , and Takeda; and has served as a consultant for Abbvie, Eli Lilly, Janssen, Takeda, Focus Medical Communications, Boehringer Ingelheim, Gilead, Imedex, Cornerstones Health, Landos Biopharma, and UCB Biopharma SRL. Victoria Rai has nothing to disclose. Corey A. Siegel has received grant support from the Crohn{\textquoteright}s and Colitis Foundation , Broad Medical Research Program , Abbvie , Janssen , Pfizer, and Takeda; and has served as consultant for Abbvie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Pfizer, Prometheus, Sebela, and Takeda. Funding Information: Conflicts of interest The authors have made the following disclosures: David Rubin, Maria Abreu, and Corey Siegel are members of IOIBD. In addition, they have the following disclosures. David T. Rubin has received grant support from Takeda; has served as a consultant for Abbvie, Abgenomics, Allergan Inc., Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., GlaxoSmithKline Services, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc. Maria T. Abreu has received grant support from Prometheus Laboratories, Pfizer, and Takeda; and has served as a consultant for Abbvie, Eli Lilly, Janssen, Takeda, Focus Medical Communications, Boehringer Ingelheim, Gilead, Imedex, Cornerstones Health, Landos Biopharma, and UCB Biopharma SRL. Victoria Rai has nothing to disclose. Corey A. Siegel has received grant support from the Crohn's and Colitis Foundation, Broad Medical Research Program, Abbvie, Janssen, Pfizer, and Takeda; and has served as consultant for Abbvie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Pfizer, Prometheus, Sebela, and Takeda.",

year = "2020",

month = jul,

doi = "10.1053/j.gastro.2020.04.002",

language = "American English",

volume = "159",

pages = "6--13.e6",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic

T2 - Results of an International Meeting

AU - International Organization for the Study of Inflammatory Bowel Disease

AU - Rubin, David T.

AU - Abreu, Maria T.

AU - Rai, Victoria

AU - Siegel, Corey A.

AU - Ahuja, Vineet

AU - Allez, Matthieu

AU - Ananthakrishnan, Ashwin N.

AU - Bernstein, Charles N.

AU - Braun, Jonathan G.

AU - Chowers, Yehuda

AU - Colombel, Jean Frederic

AU - Danese, Silvio

AU - D'Haens, Geert

AU - D'Hoore, Andre

AU - Dignass, Axel

AU - Dotan, Iris

AU - Dubinsky, Marla C.

AU - Ekbom, Anders

AU - Fleshner, Phillip R.

AU - Gassull, Miquel A.

AU - Gearry, Richard B.

AU - Ghosh, Subrata

AU - Griffiths, Anne M.

AU - Halfvarson, Jonas

AU - Hanauer, Stephen B.

AU - Harpaz, Noam

AU - Hart, Ailsa

AU - Kamm, Michael A.

AU - Kaplan, Gil G.

AU - Koutroubakis, Ioannis

AU - Lakatos, Peter L.

AU - Levine, Arie

AU - Lewis, James D.

AU - Lindsay, James O.

AU - Loftus, Edward V.

AU - Louis, Edouard

AU - Lukas, Milan

AU - Magro, Fernando

AU - Mahadevan, Uma

AU - Mantzaris, Gerasimos J.

AU - McGovern, Dermot P.

AU - Moum, Bjørn A.

AU - Munkholm, Pia

AU - Neurath, Markus F.

AU - Ng, Siew C.

AU - O'Morain, Colm

AU - Panaccione, Remo

AU - Panes, Julian

AU - Peyrin-Biroulet, Laurent

AU - Turner, Dan

N1 - Funding Information: Conflicts of interest The authors have made the following disclosures: David Rubin, Maria Abreu, and Corey Siegel are members of IOIBD. In addition, they have the following disclosures. David T. Rubin has received grant support from Takeda ; has served as a consultant for Abbvie, Abgenomics, Allergan Inc., Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., GlaxoSmithKline Services, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc. Maria T. Abreu has received grant support from Prometheus Laboratories , Pfizer , and Takeda; and has served as a consultant for Abbvie, Eli Lilly, Janssen, Takeda, Focus Medical Communications, Boehringer Ingelheim, Gilead, Imedex, Cornerstones Health, Landos Biopharma, and UCB Biopharma SRL. Victoria Rai has nothing to disclose. Corey A. Siegel has received grant support from the Crohn’s and Colitis Foundation , Broad Medical Research Program , Abbvie , Janssen , Pfizer, and Takeda; and has served as consultant for Abbvie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Pfizer, Prometheus, Sebela, and Takeda. Funding Information: Conflicts of interest The authors have made the following disclosures: David Rubin, Maria Abreu, and Corey Siegel are members of IOIBD. In addition, they have the following disclosures. David T. Rubin has received grant support from Takeda; has served as a consultant for Abbvie, Abgenomics, Allergan Inc., Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., GlaxoSmithKline Services, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc. Maria T. Abreu has received grant support from Prometheus Laboratories, Pfizer, and Takeda; and has served as a consultant for Abbvie, Eli Lilly, Janssen, Takeda, Focus Medical Communications, Boehringer Ingelheim, Gilead, Imedex, Cornerstones Health, Landos Biopharma, and UCB Biopharma SRL. Victoria Rai has nothing to disclose. Corey A. Siegel has received grant support from the Crohn's and Colitis Foundation, Broad Medical Research Program, Abbvie, Janssen, Pfizer, and Takeda; and has served as consultant for Abbvie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Pfizer, Prometheus, Sebela, and Takeda.

PY - 2020/7

Y1 - 2020/7

UR - http://www.scopus.com/inward/record.url?scp=85088117889&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2020.04.002

DO - 10.1053/j.gastro.2020.04.002

M3 - Editorial

C2 - 32272113

AN - SCOPUS:85088117889

SN - 0016-5085

VL - 159

SP - 6-13.e6

JO - Gastroenterology

JF - Gastroenterology

IS - 1

ER -

Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

Bibliographical note

Access to Document

Other files and links

Cite this